Price
No data yet.
Social Signal Score
Analyst Ratings
22 analystsRevenue
$57.48M+1025.29%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Harout Semerjian
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 258
- Beta
- 0.60
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -2.44
Financials
Revenue
$57.48M+1025.3%Net Income
$-16.68MEBITDA
$-12.35MFree Cash Flow
$-16.05MEPS (diluted)
$-0.02Shares Outstanding (diluted)
670.70M+321.4%Operating Expenses
$60.89MCash & Debt
$300.85MRevenue by Segment (annual)
$335.27MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $183.88M | $-85.78M | $-0.13 |
| 2024 | $76.99M | $-174.57M | $-0.27 |
| 2023 | $237.0K | $-184.13M | $-0.32 |
| 2022 | $596.0K | $-141.90M | $-0.37 |
| 2021 | $1.39M | $-116.11M | $-0.37 |
| 2020 | $253.0K | $-75.62M | $-0.28 |
| 2019 | $460.0K | $-68.55M | $-0.33 |
| 2018 | $1.07M | $-27.02M | $-0.15 |
| 2017 | $1.06M | $-27.92M | $-0.18 |
| 2016 | $6.16M | $-29.54M | $-0.19 |
| 2015 | $36.37M | $46.0K | $0.00 |
| 2014 | $1.15M | $-35.67M | $-0.23 |
| 2013 | $1.28M | $-38.38M | $-0.30 |
| 2012 | $2.71M | $-68.88M | $-0.54 |
Valuation
GERNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
30-78.57%Social Signal Score
Mentions (6)
- Newsglobenewswire.com·17d ago·Negative
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) FOSTER CITY, Calif., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today reported that, effective September 17, 2026, it granted stock options to purchase an aggregate of 821,250 shares of common stock to nine newly hired employees as an inducement material to such employees' ac…
View source ↗ - Newsmarketbeat.com·20d ago·Neutral
Geron Eyes High End of 2026 RYTELO Revenue Guidance as Community Adoption Expands Geron NASDAQ: GERN executives said the company remains on track to generate 2026 RYTELO net revenue of $220 million to $240 million, with Chief Executive Officer Harout Semerjian saying the company now expects results toward the midpoint to high end of that range, or approximately $230 million to $240 million.
View source ↗ - Newsmarketbeat.com·22d ago·Neutral
Geron Sees RYTELO Revenue Near High End of 2026 Guidance as Community Use Expands Geron NASDAQ: GERN said it expects full-year net revenue from RYTELO to land in the mid-to-high end of its previously stated range, or approximately $230 million to $240 million, as the company continues to expand use of the telomerase inhibitor in lower-risk myelodysplastic syndromes, or MDS.
View source ↗ - Newsglobenewswire.com·34d ago·Neutral
Geron to Present at Upcoming Investor Conferences FOSTER CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announced that members of the management team are scheduled to participate in the following upcoming investor conferences:
View source ↗ - Newsglobenewswire.com·48d ago·Negative
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) FOSTER CITY, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective August 17, 2026, it granted stock options to purchase an aggregate of 311,250 shares of common stock to six newly hired employees as an inducement material to such employees' acceptance of employment with Geron.
View source ↗ - Newsseekingalpha.com·48d ago·Neutral
…s Plan Taking Shape As Competition Heats Up In Myelofibrosis Genron Corp. reported Q2'26 net product revenues of $57.5M from U.S. sales of Rytelo, up 11% from Q1'26. GERN's management did not increase its 2026 revenue guidance, but did suggest revenues were likely to reach the mid- to high-end of that guidance. A potential competitor in myelofibrosis, KPTI, is looking to file for approval in frontline myelofibrosis, while GERN is running its phase 3 study in relapsed/refractory myelofibrosis.
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $-0.01 per share
Typical surprise +21.6% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$-0.02 vs $-0.01miss
- Wed, May 6$-0.01 vs $-0.03beat
- Wed, Feb 25$-0.03 vs $-0.03beat
- Wed, Nov 5$-0.03 vs $-0.04beat
- Wed, Aug 6$-0.02 vs $-0.03beat
- Wed, May 7$-0.03 vs $-0.04beat
Estimates and results for GERN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by GERN officers and directors.
- Bought
- $222k
- Sold
- $8.9m
4 trades
6 trades
- Robertson Michellesold
- Lawlis V Bryanbought
- Samuels Scott Alanbought
- Scarlett John Abought
- Ziegler Jamesbought
- Grethlein Andrew Jsold
- Feller Fayesold
- Kapur Anilsold
90 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in GERN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.